Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nesiritide: harmful or harmless?

Michael P Dorsch1, Jo Ellen Rodgers

  • 1Department of Pharmacy Services, University of Michigan Hospitals and Health Clinics, Ann Arbor, Michigan 48109-0008, USA. mdorsch@med.umich.edu

Pharmacotherapy
|September 27, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Implicit Bias in Shaping Medication Prescribing Practices: A Scoping Review.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

The impact of data source on real-world medication adherence and exposure measures: From prescription to sold.

Journal of managed care & specialty pharmacy·2026
Same author

Rapid quantitative urinary chloride sensing with conductivity correction for cardiac patient management.

Biosensors & bioelectronics·2026
Same author

Patient and Clinician Attitudes Toward Mobile Health Apps: Qualitative Study.

JMIR mHealth and uHealth·2026
Same author

Evaluating patient acceptability of clinical pharmacist engagement following clinical decision support.

Exploratory research in clinical and social pharmacy·2026
Same author

Guideline-Directed Medical Therapies Among Patients With Heart Failure Enrolled in Cardiac Rehabilitation.

Journal of cardiopulmonary rehabilitation and prevention·2026
Same journal

Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

Response to Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
See all related articles

Nesiritide, a treatment for acute decompensated heart failure, may increase risks of renal dysfunction and mortality. Further clinical trials are needed to clarify its safety and role in heart failure management.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Nesiritide is a recombinant human B-type natriuretic peptide (BNP) used for acute decompensated heart failure.
  • It was anticipated to be a safer and more effective treatment option compared to previous therapies.

Purpose of the Study:

  • To evaluate the safety and efficacy of nesiritide in treating acute decompensated heart failure.
  • To address concerns regarding potential renal dysfunction and mortality risks associated with nesiritide therapy.

Main Methods:

  • Review of existing clinical studies and meta-analyses concerning nesiritide.
  • Analysis of data on vasodilation, diuresis, renal function, and mortality in patients treated with nesiritide.

Main Results:

  • Nesiritide administration leads to vasodilation and diuresis.

Related Experiment Videos

  • Recent meta-analyses suggest a potential increased risk of renal dysfunction and mortality with nesiritide use.

    • Conclusions:

    • Concerns regarding the safety of nesiritide, particularly renal effects and mortality, require further investigation.
    • Future clinical trials are essential to better understand nesiritide's role and safety profile in managing acute decompensated heart failure.
    • Current use of nesiritide should be limited pending further data.